Infliximab: A review of its use in the management of rheumatoid arthritis

Drugs

Volumn 59, Issue 6, 2000, Pages 1341-1359

  Markham, Anthony ^a   Lamb, Harriet M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; HEADACHE; HUMAN; INFECTION RISK; LYMPHOCYTE MIGRATION; NAUSEA; NEOVASCULARIZATION (PATHOLOGY); PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 0034131049     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200059060-00010     Document Type: Review

References (54)

1. 1. Feldmann M, Elliott MJ, Woody JN, et al. Anti-tumor necrosis factor-α therapy of rheumatoid arthritis. Adv Immunol 1997; 64: 283-350
2. 2. van der Heijde DMFM. Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol 1995; 34 Suppl. 2: 74-8
3. 3. Maini RN. The role of cytokines in rheumatoid arthritis: the Croonian Lecture 1995. J R Coll Physicians Lond 1996 JulAug; 30: 344-51
4. 4. Ohshima S, Saeki Y, Mima T, et al. Possible mechanism for the long-term efficacy of anti-TNF-α antibody therapy (cA2) in RA [abstract no. 1289]. Arthritis Rheum 1996 Sep; 39 Suppl.: S242
5. 5. Furst DE, Breedveld FC, Kalden JR, et al. Building towards a consensus for the use of tumour necrosis factor blocking agents. Ann Rheum Dis 1999; 58 (12): 725-6
6. 6. Jarvis B, Faulds D. Etanercept: a review of its use in rheumatoid arthritis. Drugs 1999 Jun; 57 (6): 945-66
7. 7. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30 (16): 1443-53
8. 8. Onrust SV, Lamb HM. Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. BioDrugs 1998 Nov; 10: 397-422
9. 9. Harriman G, Harper LK, SchaibleTF. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNF α treatment. Ann Rheum Dis 1999; 58 Suppl. 1: I61-4
10. 10. Dalesandro MR, Kinney CS, Frederick B, et al. Potential clinical relevance of the mechanism of inhibition of immune function by the mouse/human chimeric anti-TNF-α antibody, cA2 [abstract no. 1484]. Arthritis Rheum 1995 Sep; 38 Suppl.: S401
11. 11. Maini RN, Taylor PC, Paleolog E, et al. Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis. Ann Rheum Dis 1999; 58 Suppl. I: I56-60
12. 12. Feldmann M, Paleolog E, Taylor P, et al. The mechanism of action of anti-TNF-α therapy in rheumatoid arthritis [abstract no. SH 1.5]. Naunyn Schmiedebergs Arch Pharmacol 1998; 358 (1) Suppl. 1 : R197
13. 13. Lorenz H-M, Antoni C, Valerius T, et al. In vivo blockade of TNF-α by intravenous infusion of a chimeric monoclonal TNF-α antibody in patients with rheumatoid arthritis: short term cellular and molecular effects. J Immunol 1996 Feb 15; 156: 1646-53
14. 14. Paleolog EM, Hunt M, Elliot MJ, et al. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor α antibody in rheumatoid arthritis. Arthritis Rheum 1996 Jul; 39: 1082-91
15. 15. Brennan FM, Browne KA, Green PA, et al. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-α (cA2) therapy. Br J Rheumatol 1997 Jun; 36: 643-50
16. 16. Perkins DJ, St Clair EW, Misukonis MA, et al. Reduction of NOS2 overexpression in rheumatoid arthritis patients treated with anti-tumor necrosis factor α monoclonal antibody (cA2). Arthritis Rheum 1998 Dec; 41: 2205-10
17. 17. Taylor PC, Chapman P, Elliott MJ, et al. Reduced granulocyte traffic and chemotactic gradients in rheumatoid joints following treatment with anti-TNF-α monoclonal antibody [abstract no. 50]. Br J Rheumatol 1998; 37 Suppl. 1: 29
18. 18. Tak PP, Taylor C, Breedveld FC, et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor-α monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996 Jul; 39: 1077-81
19. 19. Tak PP, Taylor PC, Breedveld FC, et al. Infiltrate analysis of rheumatoid synovial tissue before and after anti-TNFA monoclonal antibody treatment [abstract no. 196]. Arthritis Rheum 1995 Sep; 38 Suppl.: S185
20. 20. Lorenz H-M, Hieronymus T, Grunke M, et al. In vivo blockade of TNF-α in patients with rheumatoid arthritis: indication for tachyphylaxis in long term ex vivo and in vitro effects after repeated infusion of chimeric monoclonal antibody cA2 [abstract no. P12]. Ann Rheum Dis 1998 Mar; 57: 190
21. + T cells in the peripheral blood [abstract no. 798]. Arthritis Rheum 1998 Sep; 41 Suppl.: S165
22. 22. Maini RN, Elliott MJ, Long-Fox A, et al. Clinical response of rheumatoid arthritis (RA) to anti-TNF-α monoclonal antibody (mab) is related to administered dose and persistence of circulating antibody [abstract no. 200]. Arthritis Rheum 1995 Sep; 38 Suppl.: S186
23. 23. Paleolog E, Young S, McCloskey RV, et al. Angiogenesis as a therapeutic target in rheumatoid arthritis: serum vascular endothelial growth factor is decreased by anti-TNF-α therapy [abstract no. 147]. Clin Exp Rheumatol 1998 Mar-Apr; 16: 232
24. 24. Hawkey CJ, Stack WA. Chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease [letter]. N Engl J Med 1998 Jan 29; 338: 333-4
25. 25. Targan SR, Schaible TF. Chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease [reply letter]. N Engl J Med 1998 Jan 29; 338: 334
26. 26. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994 Oct 22; 344: 1105-10
27. 27. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998 Sep; 41: 1552-63
28. 28. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999 Dec 4; 354: 1932-9
29. 29. Kavanaugh A, St Clair EW, McCune WJ, et al. Chimeric anti-tumor necrosis factor-α monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol 2000; 27 (4): 841-50
30. TM (infliximab) for IV injection. Malvern (PA), USA; Nov 1999
31. 31. Rezaian MM. Do infliximab and methotrexate act synergistically in the treatment of rheumatoid arthritis? [letter]. Arthritis Rheum 1999 Aug; 42: 1779
32. 32. Maini RN, Feldmann M, Schaible T, et al. Do infliximab and methotrexate act synergistically in the treatment of rheumatoid arthritis? [reply letter]. Arthritis Rheum 1999 Aug; 42: 1779-80
33. 33. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 1993 Dec; 36: 1681-90
34. 34. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995 Jun; 38 (6): 727-35
35. 35. Paulus HE, Egger MJ, Ward JR, et al. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 1990 Apr; 33 (4): 477-84
36. 36. Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 1994 Oct 22; 344: 1125-7
37. RM) in patients with active RA despite methotrexate [abstract no. 1980]. Arthritis Rheum 1999 Sep; 42 Suppl.: S401
38. 38. Antoni C, Maini R, Breedveld F, et al. Subgroup analyses show consistent clinical benefit in a 30-week double blind trial (ATTRACT) with an anti-TNF-α monoclonal antibody, infliximab, in rheumatoid arthritis patients on methotrexate [abstract no. 905]. Ann Rheum Dis 1999 Jun 6: 217
39. TM stops progression of rheumatoid arthritis [media release]; 15 Nov 1999 [3 pages]
40. 40. Hanauer SB. Safety of infliximab in clinical trials. Aliment Pharmacol Ther 1999; 13 Suppl. 4: 16-22
41. 41. Locksley RM, Wilson CB. Cell-mediated immunity and its role in host defense. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 4th ed. v. 1. New York: Churchill Livingstone, 1995: 102-48
42. 42. Barland P, Lipstein E. Selection and use of laboratory tests in the rheumatic diseases. Am J Med 1996 Feb 26; 100 Suppl. 2A: 16S-23S
43. 43. Hahn BH. Systemic lupus erythematosus. In: Wilson JD, Braunwald E, Isselbacher KJ, editors. Principles of internal medicine. 12th ed. v. 2. New York: McGraw-Hill, Inc., 1991: 1432-7
44. alpha [abstract no. B114]. Rheumatol Eur 1995; 24 Suppl. 3: 108
45. 45. Smolen JS, Steiner G, Breedveld FC, et al. Anti-TNFα therapy and drug induced lupus-like syndrome [abstract no. 906]. Ann Rheum Dis 1999 Jun 6; EULAR Suppl.: 217
46. 46. Pincus T, O'Dell JR, Kremer JM. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. Ann Intern Med 1999 Nov 16; 131: 768-74
47. 47. Pincus T, Callahan LF. Taking mortality in rheumatoid arthritis seriously - predictive markers, socioeconomic status and comorbidity. J Rheumatol 1986; 13: 841-5
48. 48. Huizinga TWJ, Breedveld FC. Cytokine-suppressive anti-inflammatory drugs: status of development in rheumatoid arthritis. Clin Immunother 1996 Nov; 6: 395-404
49. 49. Brooks PM. The Heberden oration 1997 treatment of rheumatoid arthritis: from symptomatic relief to potential cure. Br J Rheumatol 1998 Dec; 37: 1265-71
50. 50. Markham A, Faulds D. Methotrexate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in rheumatoid arthritis and other immunoregulatory disorders. Clin Immunother 1994; 1 (3): 217-44
51. 51. Furst DE. The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases. Br J Rheumatol 1997 Nov; 36: 1196-204
52. 52. Furst DE, Keystone E, Maini RN, et al. Recapitulation of the round-table discussion - assessing the role of anti-tumour necrosis factor therapy in the treatment of rheumatoid arthritis. Rheumatology 1999; 38 Suppl. 2: 50-3
53. 53. Furst DE, Breedveld FC, Burmester GR, et al. Access to disease modifying treatments for rheumatoid arthritis patients. Ann Rheum Dis 1999; 58 Suppl. I: I129-30
54. R: etanercept prescribing information. Seattle (WA); May 1999